Can levetiracetam cause syncope or fainting episodes?

Can Levetiracetam Cause Fainting Symptoms?

Levetiracetam can cause hypotension and cardiovascular effects that may lead to fainting, though this is uncommon and primarily documented in overdose situations or when administered intravenously at high doses.

Cardiovascular Effects in Clinical Use

The most robust safety data comes from the ESETT trial 1, which found that life-threatening hypotension occurred in only 0.7% of patients receiving intravenous levetiracetam for status epilepticus, compared to 3.2% with fosphenytoin and 1.6% with valproate. Cardiac arrhythmias were similarly rare at 0.7% 1.

Key Clinical Context:

• Standard therapeutic use: The FDA drug label 2 lists dizziness (9% vs 4% placebo) and vertigo (3% vs 1% placebo) as documented adverse effects, but does not list syncope or hypotension as common adverse events in therapeutic dosing
• Somnolence (15% vs 8% placebo) and asthenia (weakness/fatigue) are the most common side effects that could theoretically contribute to falls or presyncope 2

When Cardiovascular Effects Occur

Hypotension and bradycardia are primarily documented in three specific scenarios:

1. Overdose situations: A case report 3 documented bradycardia and hypotension in a patient who ingested 60-80g of levetiracetam (463 mcg/mL serum level vs therapeutic 10-40 mcg/mL). The cardiovascular toxicity responded to atropine and IV fluids, suggesting a possible muscarinic receptor mechanism at very high concentrations.

2. Rapid IV administration: During perioperative use 4, levetiracetam showed significantly less blood pressure drop compared to phenytoin, which caused marked hypotension during anesthesia (P=0.001).

3. Rare cardiac events: One case report 5 documented torsades de pointes and cardiac arrest after levetiracetam administration, though this represents an extremely rare occurrence.

Clinical Implications

For patients on standard oral doses (500-3000 mg/day):

• True syncope from levetiracetam is not a recognized common adverse effect
• Dizziness and somnolence may contribute to falls or near-syncope, particularly during the first 4 weeks of treatment 2
• If a patient reports fainting on levetiracetam, investigate other causes first (cardiac arrhythmia, orthostatic hypotension from other medications, seizure-related phenomena)

Common pitfalls to avoid:

• Do not automatically attribute syncope to levetiracetam without ruling out actual seizure activity, cardiac causes, or medication interactions
• Be aware that behavioral and psychiatric effects (depression, anxiety, agitation) are far more common than cardiovascular effects 2, 6
• Monitor more closely during initial titration when CNS effects peak

If cardiovascular symptoms occur:

• Check serum levetiracetam levels if overdose is suspected
• Consider dose reduction or switching to alternative antiseizure medications (lacosamide, brivaracetam) 6
• Evaluate for drug interactions, though levetiracetam has minimal pharmacokinetic interactions 2